applsci-logo

Journal Browser

Journal Browser

Prevention and Treatment of Medical Diseases in Vulnerable Populations: 2nd Edition

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Biomedical Engineering".

Deadline for manuscript submissions: 20 October 2025 | Viewed by 449

Special Issue Editors


E-Mail Website
Guest Editor
Department of Oral and Maxillo-facial Sciences, Sapienza University of Rome, 00185 Roma, Italy
Interests: oral medicine; oral pathology; oral surgery; laser; photobiomodulation photo; public health; prevention
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Oral and Maxillo-facial Sciences, Sapienza University of Rome, 00185 Roma, Italy
Interests: oral cancer

Special Issue Information

Dear Colleagues,

The main topics of this Special Issue will be medical diseases in vulnerable populations, including migrants, ethnical and social minorities, and people experiencing homelessness. In this Special Issue, we aim to publish reviews, original articles, clinical studies, case reports, and case series that could help clinicians to better understand the pathology, etiology, diagnosis, prevention, and management of medical conditions in vulnerable populations. Many of these persons are especially fragile, including refugees, children, women, and disabled people, and very little is known about the healthcare needs of these groups.

This Special Issue is an opportunity to discuss recent findings to improve clinical decision-making and the care of medical disorders affecting this target population from studies conducted worldwide. Review papers are also welcome.

Dr. Gaspare Palaia
Dr. Daniele Pergolini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • refugee
  • migrants
  • asylum seeker
  • children
  • women
  • vulnerable populations
  • disabled
  • homelessness

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1430 KiB  
Article
Clinical Correlation Between Antihypercholesterolemic and Antihypertensive Drugs with Oral Lichenoid Lesions: Literature Review and Preliminary Retrospective Analysis
by Daniele Pergolini, Mohamed Mohsen, Federica Basile, Flaminia Marini Grassetti, Gaspare Palaia, Gianluca Tenore and Umberto Romeo
Appl. Sci. 2025, 15(7), 3750; https://doi.org/10.3390/app15073750 - 29 Mar 2025
Viewed by 226
Abstract
Despite extensive research, the exact cause of oral lichenoid lesions remains unknown. The chronic inflammatory tissue reaction mediated by T cells is the basis of the etiological process. However, oral lichenoid lesions often occur in the presence of certain drugs. Our aim was [...] Read more.
Despite extensive research, the exact cause of oral lichenoid lesions remains unknown. The chronic inflammatory tissue reaction mediated by T cells is the basis of the etiological process. However, oral lichenoid lesions often occur in the presence of certain drugs. Our aim was to conduct a preliminary retrospective study to assess the correlation between the administration of statins or HMG-inhibitor CoA reductase, which are commonly used for treating hypercholesterolemia, and the sartans or blockers of the angiotensin II receptor, which are used for treating hypertension, in relation to the occurrence of oral lichenoid lesions. This preliminary retrospective study included 2158 patients who attended the Oral Medicine and Maxillofacial Surgery (Mo-Max) Department of Oral Science and Maxillofacial Surgery, Sapienza University of Rome, from 2019 to 2022. A significant association was found between the presence of oral lichenoid lesions and the simultaneous administration of sartans and statins (χ2 = 46.49; p < 0.001). Of the 2158 patients, 118 (5.5%) were diagnosed with oral lichenoid lesions. In the analysis of standardized residues, we found that pathology developed in 16.3% of patients taking statins and 15.9% of those taking sartans. Oral lichenoid lesions only developed in 4.4% of those not taking these drugs. Full article
Show Figures

Figure 1

Back to TopTop